Caffeine consumption causes significant physiologic effects due to its antagonism of adenosine receptors. The A1 adenosine receptor is coupled in an inhibitory manner to adenylate cyclase. To study the effects of chronic caffeine ingestion, rats were provided with 0.1% caffeine drinking solution for 28 d. The A1 adenosine receptor agonist radioligand [3H]phenylisopropyladenosine identifies two affinity states in control rat cerebral cortex membranes with a high affinity dissociation constant (KH) of 0.40 +/-0.08 nM and low affinity dissociation constant (KL) of 13.7 +/-3.9 nM, with 33% of the receptors in the high affinity state. In membranes from caffeine-treated animals, all of the A1 receptors are shifted to the high affinity state with a dissociation constant (KD) of 0.59 +/-0.06 nM. Guanylylimidodiphosphate (10(-4) M) decreases binding by 43% in control membrane, with no change in KH or KL, while membrane binding in caffeine-treated animals decreases by 45% with a threefold shift in KD to 1.5 +/-0.3 nM. Concomitant with the enhanced high affinity A1 receptor state and increased sensitivity to guanine nucleotides, membranes from treated animals show a 35% enhancement in (-)-N6-(R-phenylisopropyl)adenosine-mediated inhibition of adenylate cyclase compared with controls (P less than 0.03). Photoaffinity crosslinking the receptors with [125I]N6-2-(3-iodo-4-aminophenyl)ethyladenosine reveals that A1 receptors from both groups migrate as Mr 38,000 proteins. (-)-N'-(R-phenylisopropyl)adenosine-mediated inhibition of adenylate cyclase compared with controls (P < 0.03). Photoaffinity crosslinking the receptors with I'25I1N'-243-iodo4-aminophenyl)ethyladenosine reveals that Al receptors from both groups migrate as M, 38,000 proteins. fi-adrenergic receptor binding with 1125Iliodocyanopindolol shows a decrease in the number of Pl-receptors from 233±7 fmol/mg protein in control membranes to 190±10 fmol/mg protein in treated membranes (P = 0.01). These data indicate that the adenosine receptor antagonist, caffeine, induces a compensatory sensitization of the Al receptor-adenylate cyclase system and downregulation of jBadrenergic receptors, and provides a molecular mechanism for the caffeine withdrawal syndrome. Introduction
was previously thought to be caused by phosphodiesterase inhibition, it is now generally accepted that many of the effects of caffeine are mediated through antagonism ofadenosine receptors (AR)' (12, 13) . Two subtypes of ARs are generally recognized, the Al and the A2. These subtypes can be defined by their relative affinities for adenosine agonist analogs. Thus, the A AR displays an agonist potency series of (-)N6-(R-phenylisopropyl) adenosine (R-PIA) > N-ethylcarboxyamidoadenosine (NECA) > S-PIA, while the A2 receptor's potency series is NECA > R-PIA > S-PIA ( 14) . Both of these subtypes are coupled to the enzyme adenylate cyclase: the A1AR in an inhibitory fashion and the A2AR in a stimulatory manner.
[3H]PIA is an AR agonist radioligand selective for the AAR and has been utilized to quantitate AAR in a variety of tissues (15) . In most adenylate cyclasecoupled receptor systems, agonists distinguish two affinity forms of the receptor, a high affinity form (RH) and a low affinity form (RL) (16) . The high affinity state is thought to represent a ternary complex of agonist-receptor and guanine nucleotide binding protein (N), while the low affinity form is a binding complex of hormone and receptor (16) . The AIAR appears to be similar to other adenylate cyclase-coupled receptors in that two agonist affinity states are definable; however, A, and the inhibitory N protein (Nj) are tightly coupled even in the absence of agonists and some agonist high affinity binding is manifested even in the presence of guanine nucleotides (17) . The cellular actions of adenosine, acting via the AAR, include inhibition of adenylate cyclase activity in heart, fat, and brain tissue (18, 19) , attenuation of epinephrine-dependent adenylate cyclase activity (20) , and inhibition of the release of norepinephrine from sympathetic nerve endings (21) .
Chronic administration of AR antagonists, such as caffeine, followed by their abrupt withdrawal may produce a pathophysiologic condition characterized by an increased sensitivity to endogenous adenosine. This supersensitivity is likely analogous to that reported in the "propranolol withdrawal syndrome" following the abrupt removal of(3-adrenergic antagonists (22) . The "propranolol withdrawal syndrome" has been described clinically (22, 23) , but the biochemical mechanisms responsible for this syndrome remain a matter of debate (16) . A "caffeine withdrawal syndrome" has likewise been described in man with symptoms such as headache, myalgias, fatigue, and anxiety, but the mechanisms responsible for this syndrome remain largely unknown (10, (24) (25) (26) (27) . In the present study, we chronically administered caffeine to rats and examined its effects on the AIARadenylate cyclase system in rat cerebral cortex. The results in- Membrane preparations. The rats were decapitated and the cerebral cortex was rapidly dissected out and placed in ice-cold 50 mM Tris-HCl (pH 7.4 at 5°C) with l1-0 M phenylmethylsulfonylfluoride. The brain was minced and homogenized with 10 strokes using a motor driven glass-teflon homogenizer on ice. The homogenate was then passed through four layers of cheesecloth, washed in 40 ml of the above buffer, and centrifuged at 39,000 g for 10 min. The pellet was resuspended with 40 ml of buffer and recentrifuged (as above). Membranes used for saturation curves were resuspended at 4 ml/cortex in 50 mM Tris-HCI (pH 7.4 at 37°C), I0mM MgCl2, 1 mM EDTA, and 5.0 U/ml adenosine deaminase, and incubated at 37°C for 30 min. The membranes were then diluted to -2 mg protein/ml and either utilized immediately or frozen in liquid N2 and stored at -80°C for a maximum of 2 wk. Membranes used for adenylate cyclase assays were resuspended at 4 ml/cortex in 50 mM Tris-HCI (pH 7.4 at 37°C), 10 mM MgC12, I mM EDTA, 10 U/ml adenosine deaminase, and 4 mM dithiothreitol (DTT), and incubated at 37°C for 15 were terminated by rapid filtration over Whatman GF/C glass fiber filters and four washes with 3 ml of buffer. Filters were suspended in 10 ml of scintillation fluid and counted in a Packard scintillation counter (Packard Instrument Co., Downers Grove, IL) with an efficiency of60%. Saturation curves were analyzed by computer-assisted techniques as previously published and validated (29, 30) . Statistical analysis ofradioligand binding which compares the "goodness of fit" between two parameters was determined as previously prescribed (30 (Fig. 1 B) . This based on the law of mass action, assuming either one or two affinity states for the receptor (29) . The two-state fit most appropriately describes the data (P < 0.001). This experiment is representative of 10 similar experiments. (B) Membranes were prepared from caffeine-treated animals and binding was performed as above. This curve is representative of nine similar experiments. Only a single affinity state is observed.
states were evident with no significant change in KH or KL (see Table I and Fig. 2 A) . In contrast, "caffeine-treated" membranes demonstrate a 45% decrease (P < 0.001) in total binding with a significant (P < 0.01) threefold shift in KD to lower affinity (1.5±0.3 nM). This suggests that the receptor complex is more sensitive to guanine nucleotides and the A1-N coupling in the presence of Gpp(NH)p is less tightly associated in treated membranes than in control membranes.
A shift to all high affinity agonist binding and an increased sensitivity to guanine nucleotides in treated membranes would be expected to result in the enhancement of agonist-induced biochemical responses. Therefore, we tested the ability ofR-PIA to inhibit adenylate cyclase activity in cerebral cortex homogenates. Fig. 3 demonstrates that R-PIA-mediated inhibition of basal adenylate cyclase activity is increased by 35% in treated vs. control animals. (P < 0.03). Basal activity is exactly the same in the two groups: control, 21.7±2.9 and treated, 22.7±2.9 pmol cAMP/mg protein per min. The effective concentration producing a 50% alteration (EC50) ofR-PIA demonstrates a leftward shift from 14.8 nM in control to 7.5 nM in treated animals. This change does not, however, reach statistical significance (P = 0.10). Values are given as mean±SEM. Data from treated animals are most appropriately described by a one affinity state model. Percent RH = percent of receptors in high affinity state.
To assess if the change in agonist binding might be a manifestation of an alteration in the structure of the A1AR, we photoaffinity crosslinked the receptor with ['251]APNEA in membranes from both groups. Fig. 4 demonstrates the results obtained after SDS-PAGE and autoradiography. The A1AR's from both control and treated membranes migrate as 38,000 M, proteins. This suggests that a gross alteration in the receptor-binding subunit is not responsible for the changes seen after caffeine treatment.
Caffeine ingestion has been reported to alter the quantity of (3-adrenergic receptors in brain tissue from animals. We, therefore, measured fl-adrenergic receptor number in these same animals and found a significant decrease (P = 0.01) in treated, 190±10 fmol/mg protein, vs. control, 233±7 fmol/mg protein (n = 4) membranes (Table II) 
Discussion
Chronic therapy with receptor-specific antagonists in animals and man has been reported to induce an enchanced response to agonists following removal ofthe antagonists (16) . The caffeine withdrawal syndrome represents but one example of such sensitization to agonists. The syndrome has been recognized clinically for years with the predominant symptom being characteristic headaches (27) . The essential feature of the syndrome is that individuals must consume large quantities ofcaffeine (-500 mg = 5 cups of coffee) per day until a tolerance develops and then abruptly stop intake (27) . Symptoms usually develop within 18-20 h. Furthermore, reinstitution of caffeine intake relieves symptoms within a short period of time. The biochemical mechanisms responsible for these putative "withdrawal syndromes" have remained largely speculative.
In this study, we have probed the dynamic regulation of A1AR in rat cerebral cortex following chronic treatment with the AR antagonist, caffeine. [3HJPIA saturation curves indicate that in control cerebral cortex membranes, the agonist radioligand can distinguish two discrete affinity states of the A1AR having KH (17) . This same phenomenon can be seen in the control membranes with [3H]PIA binding wherein both high and low affinity binding are evident in the presence of 10-' M Gpp(NH)p, while the total amount ofbinding is decreased (see Table I ). In contrast, lthough cerebral cortex membranes from treated animals reveal that high affinity binding is seen in the presence of Gpp(NH)p and total binding decreases by a comparable amount, the KD has increased threefold, which indicates a decreased affinity of the components of the hormone-receptor-Ni complex. The [3H]PIA-binding data thus suggest that following caffeine treatment, there is an enhancement of the number of the receptors in the high affinity state (316-629 fmol/mg protein) and that these high affinity receptor complexes are more sensitive to guanine nucleotides than the complexes in the control membranes. An enhancement of the high affinity state and an increased sensitivity to guanine nucleotides should be associated with a sensitization of agonist-induced biochemical effector interactions.
Since one of the effects of agonist-A1AR interactions in the cerebral cortex is to produce inhibition of adenylate cyclase activity, we assessed the ability ofR-PIA to inhibit adenylate cyclase activity in membranes from control and treated rats. Fig. 3 Alterations in fl-adrenergic receptor structure (following agonist-induced desensitization) have been delineated by photoaffinity labeling (16) . To assess if an alteration in the AIAR protein might be responsible for the enhanced R-N, coupling seen in this study, we photoaffinity crosslinked the AIAR with ('25T]APNEA (33) . Following SDS-PAGE and autoradiography, the A1AR from both control and caffeine-treated membranes comigrate as 38,000 Mr proteins. This suggests that there are no major alterations in receptor structure to account for the enhanced coupling.
Membranes from the treated group demonstrate a significant decrease in the number of cerebral cortex (3-adrenergic receptors.
This down-regulation of f3-adrenergic receptors has been reported by others (35-37). The mechanism responsible for this downregulation is likely related to the increased levels of norepinephrine and epinephrine induced by caffeine administration (46) .
It has been established that adenosine can inhibit the release of norepinephrine from sympathetic nerve endings via action on presynaptic terminals (46, 47) . The increased catecholamine release probably results from caffeine's antagonism of adenosine's ability to inhibit norepinephrine release.
The biochemical changes in the AR-adenylate cyclase system following chronic caffeine ingestion may provide a molecular mechanism for the "caffeine withdrawal syndrome." In response to caffeine's antagonism ofthe AIAR, the AIAR-Ni protein coupling is shifted to the high affinity state, resulting in the compensatory sensitization of AIAR-mediated inhibition ofadenylate cyclase. The caffeine-induced increase in plasma norepinephrine also causes a fl-adrenergic receptor downregulation, and probably attentuation of fl-adrenergic adenylate cyclase stimulation.
Therefore, chronic caffeine consumption, via its AR antagonism, induces compensatory alterations in the Al and fl-receptor-adenylate cyclase system, making production ofcAMP less favored. Then, after the sudden withdrawal of caffeine, enhanced adenosine-mediated effects predominant and caffeine withdrawal symptoms become evident.
